Investors should note the voting implications for Proposal No. 3, particularly that abstentions will negatively impact passage. However, no material change to corporate strategy, governance, or financials is indicated.
EXEL drugs
EXEL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $43.59entry
- T+1 · 7mo ago +5.25%α +5.91% · $45.88
- T+5 · 7mo ago +2.13%α +1.22% · $44.52
- T+20 · 6mo ago +14.32%α +10.11% · $49.83
- T+60 · 4mo ago +27.95%α +21.87% · $55.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Exelixis, Inc. filed a supplement to its definitive proxy statement to clarify the voting standard for Proposal No. 3, which relates to the approval of the Amended 2017 Plan. The clarification specifies that a majority of shares present or represented by proxy is required for approval, with abstentions counting as votes against and broker non-votes having no effect.
Key Financial Metrics
Key Facts
- The filing is a supplement to the DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders.
- The sole purpose is to correct the voting standard description for Proposal No. 3 (Amended 2017 Plan).
- The required vote is a majority of shares present or represented by proxy; abstentions count as votes against, broker non-votes have no effect.
- No other changes are made to the original proxy statement.
Financial Impact
No direct financial impact; this is a procedural clarification.
Risk Factors
- If shareholder support is close, the clarified voting standard could affect the outcome of Proposal No. 3 due to the treatment of abstentions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-025746 |
| Document: 0001628280-26-025746-index-headers.html | 0001628280-26-025746 |
| Document: 0001628280-26-025746-index.html | 0001628280-26-025746 |
| Document: 0001628280-26-025746.txt | 0001628280-26-025746 |
Track record
16 reports on EXEL
0 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +21.97% at T+60 after the Feb 28, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20266d ago SC 13G Neutral 3/10 Entry $70.58 to $70.70 Now $67.10 −4.93% ▲ +0.17% −1.15% vs SPY
- Nov 9, 20266d ago SC 13D/A Bearish 5/10 Entry $70.58 to $70.70 Now $67.10 +4.93% ▼ −0.17% +1.15% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $69.39 to $70.13 Now $67.10 −3.30% ▲ +1.07% +1.55% vs SPY
- Oct 20, 202627d ago Institutional Cluster Neutral 2/10 Entry $64.58 to $65.31 Now $67.10 +3.90% ▲ +1.13% +2.31% vs SPY
- Oct 12, 20265w ago Institutional Cluster Neutral 3/10 Entry $59.82 to $59.51 Now $67.10 +12.17% ▼ −0.52% −0.51% vs SPY
- Sep 11, 20269w ago 8-K Bearish 6/10 Entry $56.12 to $56.21 Now $67.10 −19.57% ▼ −0.16% −0.61% vs SPY
- Jun 3, 202623w ago Insider Cluster Neutral 2/10 Entry $52.39 to $52.69 Now $67.10 +28.08% ▲ +0.57% +3.17% vs SPY
- May 29, 202624w ago 8-K Neutral 3/10 Entry $50.20 to $48.49 Now $67.10 +33.67% ▼ −3.41% −3.55% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers